1

2

3
Ishikawa Rika, Okada Yuji, Kakitani Makoto: Chemically modified granulocyte colony stimulating factor.. Kirin Amgen, December 12, 1990: EP0401384-A1 (350 worldwide citation)

A new chemically modified protein consists of human granulocyte colony stimulating factor (G-CSF) (aminoacid sequence of 174 units ( or 175 with N-terminal methionine) given in the patent) (expressed by host cells from a foreign DNA sequence) bound to polyethylene glycol either through the amino gps ...


4

5
Nishimura Osamu, Fujino Masahiko: Chemically modified lymphokine and production thereof.. Takeda Chemical Industries, September 11, 1985: EP0154316-A2 (334 worldwide citation)

The invention provides chemically modified lymphokines having R &lparstr& O-CH2CH2 &rparstr& n wherein R is a protective group for the terminal oxygen and n is an optional positive integer, bonded directly to at least one primary amino group of the lymphokine moiety, and a method of producing the sa ...


6
Nandini Katre, Michael J Knauf: Solubilization of proteins for pharmaceutical compositions using polymer conjugation. Cetus Corporation, Albert P Halluin, Janet E Hasak, August 23, 1988: US04766106 (299 worldwide citation)

A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is .beta.-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without the presence of a solubilizing agent. The unconjugated protein, which is not water-soluble or not r ...


7
Richard A Berg, Frederick H Silver, James M Pachence: Collagen matrix beads for soft tissue repair. MediMatrix, Michael Ebert, June 6, 1989: US04837285 (275 worldwide citation)

Collagen-based compositions for augmenting soft tissue, wound dressings, implants, injectable formulations or other drug delivery systems, comprising resorbable collagen matrix beads, the beads having an average pore size of from 50 to 350 microns, and the collagen comprising from 1 to 30% by volume ...


8
Donald G Wallace, Susan B Wade: Collagen implant material and method for augmenting soft tissue. Collagen Corporation, Ciotti & Murashige, January 3, 1984: US04424208 (271 worldwide citation)

An injectable implant material for soft tissue augmentation comprising a dispersion of (a) particles of cross-linked atelopeptide collagen; and (b) reconstituted fibrous atelopeptide collagen in a (c) physiological aqueous carrier. Implants of this material have improved persistence relative to curr ...


9
Marshall R Urist: Biodegradable organic polymer delivery system for bone morphogenetic protein. University of California, January 7, 1986: US04563489 (258 worldwide citation)

Disclosed is a biodegradable polylactic acid polymer delivery system for delivery of bone morphogenic protein (BMP) to induce formation of new bone in viable tissue. The delivery composition is substantially pure BMP in combination with a biodegradable polylactic acid polymer and it is prepared by a ...


10
Koenig Wolfgang Dr, Seidel Heinz Ruediger Dr, Sandow Juergen Kurt Dr: Regulating peptide-containing pharmaceutical preparations with retarded release, and process for their preparation.. Hoechst, March 13, 1985: EP0133988-A2 (230 worldwide citation)

Implants containing regulatory peptides or their analogues as active ingredients and natural poly-D-(-)-3-hydroxybutyric acid as biodegradable vehicle, and process for their preparation, are described. The active ingredient undergoes protracted release from the implants.